1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025

Summary

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person’s symptoms, changes in the ST tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

GlobalData epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 million cases in 2015 to 30.62 million cases in 2025, at an Annual Growth Rate (AGR) of 2.03%. Throughout the forecast period, the diagnosed prevalent cases of ACS in the US will constitute the highest proportion in the 7MM at approximately 54%. In the 7MM, the diagnosed prevalent cases of ACS will be higher in men (61.81%) and in the age group older than 65 years (62.84%). STEMI, NSTEMI, and UA will constitute approximately 25%, 40%, and 35% of the diagnosed prevalent cases of ACS in the 7MM. In the 7MM, GlobalData epidemiologists project ACS hospitalizations to increase from 1.63 million cases in 2015 to 1.71 million cases in 2025 at an AGR of 0.51%. The US constitutes around 40% of the total hospitalized ACS cases in the 7MM for the year 2015 and will be the market with the highest number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (62.85%) and in the age group older than 65 years (69.34%). In the year 2015, about 29% of the ACS cases in the 7MM were STEMI, 44% were NSTEMI, and 25% were UA.

Scope

- The Acute coronary syndrome (ACS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015-2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).
- The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The ACS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global ACS market.
- Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ACS therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025
1 Table of Contents
1 Table of Contents 5


2 Epidemiology 9
2.1 Disease Background 9
2.2 Risk Factors and Comorbidities 10
2.3 Global Trends 13
2.3.1 ACS Diagnosed Prevalence 13
2.3.2 STEMI and NSTEMI Trends 16
2.3.3 ACS Hospitalizations 18
2.4 Forecast Methodology 19
2.4.1 Sources Used 22
2.4.2 Forecast Assumptions and Methods 29
2.4.3 Sources Not Used 42
2.5 Epidemiological Forecast for ACS (2015-2025) 43
2.5.1 Diagnosed Prevalent Cases of ACS 43
2.5.2 Age-Specific Diagnosed Prevalent Cases of ACS 46
2.5.3 Sex-Specific Diagnosed Prevalent Cases of ACS 48
2.5.4 Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA 50
2.5.5 Age-Standardized Diagnosed Prevalence of ACS 52
2.5.6 ACS Hospitalizations 53
2.5.7 Sex-Specific ACS Hospitalizations 56
2.5.8 ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA 58
2.6 Discussion 60
2.6.1 Epidemiological Forecast Insight 60
2.6.2 Limitations of the Analysis 61
2.6.3 Strengths of the Analysis 62
3 Appendix 64
3.1 Bibliography 64
3.2 About the Authors 74
3.2.1 Epidemiologists 74
3.2.2 Reviewers 74
3.2.3 Global Director of Therapy Analysis and Epidemiology 76
3.2.4 Global Head of Healthcare 76
3.3 About GlobalData 77
3.4 About EpiCast 77
3.5 Disclaimer 78

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for ACS 12
Table 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants 16
Table 3: 7MM, Sources of Diagnosed Prevalence Data for MI 22
Table 4: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI 24
Table 5: 7MM, Data Sources of ACS Hospitalizations 26
Table 6: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations 28
Table 7: 7MM, Diagnosed Prevalent Cases of ACS, Ages ?25 Years, Both Sexes, N, Select Years, 2015-2025 45
Table 8: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015 47
Table 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ?25 Years, N (Row %), 2015 49
Table 10: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages ?25 Years, N (Row %), 2015 51
Table 11: 7MM ACS Hospitalizations, Ages ?25 Years, Both Sexes, N, Select Years, 2015-2025 55
Table 12: 7MM, Sex-Specific ACS Hospitalizations, Ages ?25 Years, N (Row %), 2015 57
Table 13: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages ?25 Years, Both Sexes, N, 2015 59

1.2 List of Figures
Figure 1: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990-2008 14
Figure 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%) 16
Figure 3: Case Segmentation Map 22
Figure 4: 7MM, Diagnosed Prevalent Cases of ACS, Ages ?25 Years, Both Sexes, N, Select Years, 2015-2025 46
Figure 5; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015 48
Figure 6: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ?25 Years, N, 2015 50
Figure 7: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages ?25 Years, N, 2015 52
Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages ?25 Years, 2015 53
Figure 9: 7MM ACS Hospitalizations, Ages ?25 Years, Both Sexes, N, Select Years, 2015-2025 56
Figure 10: 7MM, Sex-Specific ACS, Ages ?25 Years, N, 2015 58
Figure 11: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages ?25 Years, Both Sexes, N, 2015 60

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.